Monograph Details
|
|
Central Nervous System
> Parkinsonism
|
|
ZELAPAR |
| Manufacturer |
|
Valeant Pharmaceuticals, Inc |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
MAO-B inhibitor. |
| Generic Name |
|
Selegiline 1.25mg; orally-disintegrating tabs; contains phenylalanine. |
| Indications |
|
Adjunct in Parkinson's disease in patients with deteriorating response to levodopa/carbidopa. |
| Children |
<16yrs: not recommended.
|
| Adults |
|
Take (without liquids) in the AM before breakfast; do not eat/drink within 5 minutes (before or after). Place tablet on tongue, do not swallow. ≥16 yrs: 1.25mg once daily for at least 6 weeks; if needed, may increase to max 2.5mg once daily if tolerated. Do not exceed max dose. Not bioequivalent to other forms of selegiline. |
| Contraindications |
|
During or within 2 weeks of meperidine, MAOIs (eg, other forms of selegiline). Concomitant tramadol, methadone, propoxyphene, dextromethorphan. |
| Precautions |
|
Renal or hepatic impairment. Monitor for melanoma. Elderly (higher risk of orthostatic hypotension). Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
See Contraindications. Avoid sympathomimetic amines, tricyclics, SSRIs, SNRIs; allow at least 14 days after discontinuing selegiline before starting an SSRI (eg, fluoxetine), tricyclic or SNRI; allow 5 weeks after discontinuing fluoxetine before starting selegiline. Caution with CYP3A4 inducers (eg, phenobarbital, phenytoin, carbamazepine, nafcillin, rifampin). Consider reducing concomitant levodopa/carbidopa dose if dyskinesia occurs. |
| Adverse Reactions |
|
Postural hypotension (usually transient), dizziness, GI upset, pain, headache, insomnia, rhinitis, stomatitis, hypertension, ECG abnormality, hallucinations. |
| How Supplied |
|
Tabs—60 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
